GWPH – GW Pharmaceuticals PLC is a biopharmaceutical company specializing in cannabinoid product platform. Its value has surged more than 130% pre-market today.
GWPH – GW Pharmaceuticals PLC
|Fundamentals||Previously closed at||38.46|
|Analysts opinion||Analysts are bullish on the stock since GW Pharma announced positive results of Phase 3 investigation of Epidiolex. Epidiolex is a pharmaceutical cannabis (cannabidol) based investigational drug for Dravet syndrome –a progressive disorder characterized by multiple seizure types, often including life-threatening status epilepticus.|
|Sentiments||Reports suggest that 1 in 20 to 1 in 40,000 people have Dravet syndrome. Due to positive news for its cure, the investor sentiments have been bullish.|
|Social Pulse||The stock has 43% higher social chatter than usual.|